A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518210-81-00

Acronym

D7029C00001

Enrollment

273

Registered

2025-09-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hepatocellular Carcinoma

Brief summary

Overall Survival (OS)

Detailed description

PFS, ORR, DoR by BICR per RECIST v1.1

Interventions

DRUGMYCOPHENOLATE MOFETIL

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

DRUGINFLIXIMAB

DRUGATEZOLIZUMAB

DRUGBEVACIZUMAB

DRUGRilvegostomig

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS)	—

Secondary

Measure	Time frame
PFS, ORR, DoR by BICR per RECIST v1.1	—

Countries

France, Germany, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026